Table 3

B-cell non-Hodgkin’s lymphoma subtypes

N totalChronic lymphocytic leukemia/small cell lymphomaLymphoplasmocytic lymphoma
(Waldenstrom macroglobulinaemia)
Marginal zone lymphomaFollicular lymphomaMantle cell lymphomaDiffuse large B-cell lymphomaBurkitt lymphoma
n% (95% CI)n% (95% CI)n% (95% CI)n% (95% CI)n% (95% CI)n% (95% CI)n% (95% CI)
Bionaïve1842815.2
(9.2 to 23.2)
42.2
(0.4 to 6.8)
10.5
(0 to 4.1)
3317.9
(11.3 to 26.6)
52.7
(0.6 to 7.6)
11361.4
(51.5 to 70.8)
00
(0 to 3.0)
TNFi1512617.2
(10.1 to 26.8)
64.0
(1.1 to 10.1)
106.6
(2.6 to 13.6)
3422.5
(14.3 to 32.6)
00
(0 to 3.6)
7549.7
(38.6 to 60.8)
00
(0 to 3.6)
RTX5120.0
(1.4 to 79.6)
120.0
(1.4 to 79.6)
00
(0 to 62.9)
120.0
(1.4 to 79.6)
00
(0 to 62.9)
240.0
(2.8 to 90.6)
00
(0 to 62.9)
TOC5240.0
(2.8 to 90.6)
00
(0 to 62.9)
00
(0 to 62.9)
00
(0 to 62.9)
00
(0 to 62.9)
360.0
(9.4 to 97.3)
00
(0 to 62.9)
ABA300
(0 to 80.7)
00
(0 to 80.7)
00
(0 to 80.7)
266.7
(5.0 to 99.8)
00
(0 to 80.7)
133.3
(0.2 to 95.0)
00
(0 to 80.7)
RA total3485716.4
(11.6 to 22.2)
113.2
(1.3 to 6.4)
113.2
(1.3 to 6.4)
7020.1
(14.7 to 26.4)
51.4
(0.3 to 4.0)
19455.8
(48.4 to 62.9)
00
(0 to 1.6)
General
population
28 74711 01938.3
(37.6 to 39.1)
18596.5
(6.1 to 6.9)
9503.3
(3.0 to 3.6)
488117.0
(16.4 to 17.6)
10123.5
(3.2 to 3.8)
853829.7
(29.0 to 30.4)
4881.7
(1.5 to 1.9)
  • ABA, abatacept; RA, rheumatoid arthritis; RTX, rituximab; TNFi, tumour necrosis factor inhibitor; TOC, tocilizumab.